About
Management team
Experts in developing gene therapies for inherited retinal disorders
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy.
The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.
Natalia Misciattelli PhD
Chief Executive Officer
Prof. Alberto Auricchio
Founder and Chief Science Officer
Dr. Jayashree Sahni
FRCOphth, EMBA, MD
Nina Kotsopoulou PhD
Chief Technical Officer
Lauren Kaskiel MBA
Chief Business Officer
Mike Murtagh
Senior Vice President Regulatory
Magda Blanco PhD, MBA
Head of Corporate Development